Literature DB >> 11426334

Efficient transduction of murine B lymphocytes and B lymphoma lines by modified adenoviral vectors: enhancement via targeting to FcR and heparan-containing proteins.

L Li1, T J Wickham, A D Keegan.   

Abstract

Murine lymphocytes are relatively refractory to efficient transfection or retroviral gene transduction. Adenovirus has been used as a vector to transduce a wide variety of cell types. Several advantages of adenoviruses are their ability to transduce non-cycling cells and to transduce the majority of cells in a population. Unfortunately, lymphocytes are not susceptible to infection with conventional adenovirus. Therefore, to express genes efficiently in murine B cells, we tested the ability of genetically modified adenovirus to transduce the beta-galactosidase gene. We found that adenovirus containing polylysine in the fiber knob was able to efficiently transduce lipopolysaccharide (LPS)-activated splenic B cells and the B lymphoma line M12.4.1; greater than 80% of the cells expressed beta-galactosidase activity. However, small resting B cells did not express activity unless treated with LPS after infection. This transduction was mediated by interaction with charged molecules since heparan-sulfate, and to a lesser degree chondroitan sulfate, inhibited the transduction. In addition, adenovirus containing a FLAG epitope in the fiber protein was used to target the FcR expressed on B cells using an anti-FLAG antibody. In the presence of anti-FLAG, the modified adenovirus was able to efficiently transduce LPS-activated B cells and several B cell lymphoma lines. Interestingly, in the absence of anti-FLAG, there was low level transduction in the LPS-blasts and in M12.4.1 that was not inhibited by soluble adenovirus fiber protein or agents that block RGD-integrin interactions. These results demonstrate that modified adenovirus efficiently transduce B lymphocytes which will be critical for targeting genes to normal or malignant B cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11426334     DOI: 10.1038/sj.gt.3301487

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  4 in total

1.  A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity.

Authors:  Adam C Palmer; Christopher Chidley; Peter K Sorger
Journal:  Elife       Date:  2019-11-19       Impact factor: 8.140

2.  Resistance of canine lymphoma cells to adenoviral infection due to reduced cell surface RGD binding integrins.

Authors:  Ann Marie O'Neill; Annette N Smith; Elizabeth A Spangler; Elizabeth M Whitley; Stephanie E Schleis; Richard C Bird; David T Curiel; Erin E Thacker; Bruce F Smith
Journal:  Cancer Biol Ther       Date:  2011-04-01       Impact factor: 4.742

Review 3.  Vector Strategies to Actualize B Cell-Based Gene Therapies.

Authors:  Amanda M Jeske; Paul Boucher; David T Curiel; James E Voss
Journal:  J Immunol       Date:  2021-08-01       Impact factor: 5.426

4.  Effects of recombinant adenovirus-mediated expression of IL-2 and IL-12 in human B lymphoma cells on co-cultured PBMC.

Authors:  Oliver Ebert; Dorothee Wilbert; Peter Buttgereit; Carsten Ziske; Dimitri Flieger; Ingo Gh Schmidt-Wolf
Journal:  Genet Vaccines Ther       Date:  2004-10-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.